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Abstract
Rationale: Low-grade inflammation and emphysema have been shown to be associated with an increased risk of lung
cancer. However, the systemic inflammatory response in patients with emphysema is still unknown.
Objective: To compare the plasma cytokine profiles in two groups of current or former smokers without airway obstruction:
a control group of individuals without computed tomography (CT) detected emphysema vs. a study group of individuals
with CT detected emphysema.
Methods: Subjects underwent a chest CT, spirometry, and determination of EGF, IL-15, IL-1ra, IL-8, MCP-1, MIP-1b, TGFa,
TNFa, and VEGF levels in plasma. Cytokine levels in each group were compared adjusting for confounding factors.
Results: 160 current smokers and former smokers without airway obstruction participated in the study: 80 without
emphysema and 80 subjects with emphysema. Adjusted group comparisons revealed significant reductions in EGF (20.317,
p = 0.01), IL-15 (20.21, p = 0.01), IL-8 (20.180, p = 0.02) and IL-1ra (20.220, p = 0.03) in subjects with emphysema and normal
spirometry.
Conclusions: Current or former smokers expressing a well-defined disease characteristic such as emphysema, has a specific
plasma cytokine profile. This includes a decrease of cytokines mainly implicated in activation of apoptosis or decrease of
immunosurveillance. This information should be taken into account when evaluated patients with tobacco respiratory
diseases.
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Introduction
Tobacco smoking is the leading preventable cause of death
worldwide [1]. Chronic Obstructive Pulmonary Disease (COPD),
lung cancer, and cardiovascular disease will be responsible for the
majority of deaths in the developed world in the coming decades
[2].
COPD is characterised by chronic airflow limitation caused
by a combination of small airway inflammation and parenchy-
mal destruction (emphysema) [3]. Since computed tomography
(CT) has been validated as a non-invasive technique capable of
identifying areas of lung parenchyma with emphysema [4],
several studies have identified a subgroup of apparently healthy
smokers who have emphysema but no airway obstruction [5,6].
Furthermore, this subgroup has the highest risk of developing
lung cancer among smokers [5,6]. It has been proposed that
systemic inflammation may play an important pathogenic role
in carcinogenesis [7], and whether individuals with emphysema
have a different inflammatory profile is unknown. We therefore
conducted this cross sectional study to investigate whether, in
comparison to smokers without emphysema; patients with
emphysema express a different plasma cytokine profile that
could explain their increased risk for lung cancer. From a
cohort of current and former smokers without airway obstruc-
tion participating in a lung cancer screening study, two distinct
groups were selected for the purpose of comparing cytokine
profiles: a study group of individuals with emphysema on the
CT, and a control group of smokers without emphysema.
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Methods
Participants in this cross sectional observational study were
randomly selected from a prospective cohort of individuals
enrolled from September 2000 to December 2009 in a lung
cancer screening study using low dose computed tomography
(LDCT) [8]. Participants were at least 40 years old, had smoked 10
pack-years or more and had no symptoms of lung cancer. Details
of the study protocol have been previously reported [9]. Briefly,
participating individuals were offered a baseline LDCT of the
chest followed by annual repeat studies for up to 10 years. All
patients completed spirometry at enrolment and a baseline,
standardized questionnaire including socio-demographic informa-
tion and smoking history. From an initial sample of 1925
participants enrolled in the screening trial, we focused on those
without airway obstruction on the initial spirometry. These
individuals were further classified into two groups according to
the presence or absence of emphysema on the LDCT (see flow
chart in Figure 1). Thus, the study group had smokers and former
smokers with emphysema on the LDCT but no evidence of airway
obstruction, whereas the comparison group was made out of
current and former smokers without emphysema and without
obstruction. For the purpose of this study 80 individuals were
randomly selected (http://www.randomizer.org/) from each of
these two groups. Figure 1 shows the study flow chart with the
selection process. The study protocol (IRB nu092/2009) was
approved by the institutional ethics committee of the University of
Navarra. All subjects signed an informed consent prior to
participation.
Low-Dose Computed Tomography
LDCT examinations were performed in a single breath-hold at
end-inspiration with a multidetector CT scanner (Somatom
Volume Zoom or Somatom Sensation 64, Siemens Medical
Solutions, Forchheim, Germany) at low-radiation-dose settings
(120 kVp, 20–40 mAs). All CT scans were reconstructed with
1.25-mm slice thickness and 1 mm intervals using a high spatial
frequency reconstruction algorithm. Images were displayed at
window settings appropriate for viewing the lung parenchyma
(window width of 1,500 HU and window center of2650 HU). All
images were read by two expert chest radiologists for visual
assessment of the presence of emphysema, using validated criteria
[10]. The extent of emphysema was graded ranging from no
emphysema (0) to a maximum score of 4 indicating the presence of
emphysema in more than 75% of the lung. For the purpose of this
study, patients with a score $1 were classified as having
emphysema.
Spirometry Testing
Airway function was measured at baseline in all study
participants using a flow spirometer (Vmax 22; SensorMedics,
Yorba Linda, CA) according to American Thoracic Society
standards [11]. Forced expiratory volume in the first second
(FEV1) and forced vital capacity (FVC) values were expressed as a
percentage of the predicted reference value according to the
European Community Lung Health Survey [12]. Subjects with a
postbronchodilator FEV1/FVC ratio ,70% were classified as
having airway obstruction following the criteria established by the
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
[13].
Cytokine Determinations
Plasma from all study participants was collected into Vacutai-
nerH tubes. Blood specimens were centrifuged (20006g), and
aliquots stored at –80uC until laboratory analysis was performed.
Six plasma samples (1 from those without emphysema) were not
Figure 1. Flow chart showing the selection process of study participants.
doi:10.1371/journal.pone.0060260.g001
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available or in appropriate conditions to be analyzed. Plasma
levels of epidermal growth factor (EGF), interleukin 15 (IL-15),
interleukin 1 receptor antagonist (IL-1ra), interleukin 8 (IL-8),
macrophage chemotactic protein 1 (MCP-1), macrophage inflam-
matory protein 1 b (MIP-1b), tumor growth factor a (TGFa),
tumor necrosis factor a (TNFa) and vascular endothelial growth
factor (VEGF) were measured using MILLIPLEXTM MAP kit
(Millipore, Billerica, MA, USA) with LUMINEXH Xmap
technology according to the manufacturer’s instructions [14].
The detection limits were 3.2 pg/mL, 2.5 pg/mL, 3.2 pg/mL,
2.04 pg/mL, 3.2 pg/mL, 3.2 pg/mL, 1.64 pg/mL, 2 pg/mL and
16.0 pg/mL, respectively. A LUMINEXH 100 IS System (Lumi-
nex, Austin, TX, USA) was used to read the samples, compute
standard curves and estimate cytokine concentrations. The intra-
assay coefficient of variation for all assays was less than 10%. All
the assays were carried out including samples for the four groups
in analysis in each plate, and were randomly distributed, in order
to minimise the effect of inter-assay variability.
Several studies have described markers such as TNFa, TGFa,
IL-1ra and IL-8 as representative of the systemic inflammation
present in patients with COPD/emphysema [15]. Other chemo-
kines (IL-15, MCP-1, MIP-1b) and growth factors (EGF and
VEGF) could be of interest for their putative role in the attraction
and activation of leukocytes into inflamed tissue and could
represent a systemic inflammatory link between emphysema and
associated comorbidities such as lung cancer or cardiovascular
disease. Therefore, biomarkers were selected based on these
biological criteria and on the results from a study using high
throughput proteomic analysis, in which patients with COPD/
emphysema differed from smokers and non-smokers without
airflow obstruction in the plasma levels of 25 biomarkers [16]
associated with clinically relevant parameters.
Statistical Analysis
Quantitative measurements are presented as mean (SD) for
variables with normal distribution and median (IQR) for those not
normally distributed. Categorical variables are shown along with
their percentages. Comparisons between groups were made using
Kruskal-Wallis test and Chi Square test for continuous and
categorical demographic variables, respectively. Cytokine levels
were not normally distributed and therefore were log-transformed
for the purpose of comparison between groups and regression
analyses. Univariate linear regression analyses were performed
taking the log-transformed values of each plasma cytokine level as
the dependent variable and individual variables (sex, age, pack-
years and smoking status) as independent variables. Univariate
analysis determines the strength of the association of emphysema
with each of the cytokine level adjusting for factors that were
statistical significant in the previous analysis: sex (EGF, MIP-
1beta), age (VGF) and smoking status (TGFa). Significance was
established as a two-tailed p-value # 0.05 for all the analyses.
Calculations were made using Stata statistical sotfware (version
10.1; Stata, College Station, TX).
Results
One hundred and sixty current and former smokers participated
in the study. Patient characteristics and physiologic measurements
of both groups are shown in Table 1. Subjects were predominantly
male. No differences were observed for age, cumulative tobacco
exposure or smoking status at the time of the evaluation. Subjects
with emphysema had lower absolute values of FEV1 but their
predictive values of lung function were similar.
Table 2 shows groups comparison of their plasmatic cytokines
levels. Compared to control smokers, individuals with emphysema
had significantly lower log-transformed concentrations of IL-1ra,
IL-8 and IL-15. Table 3 shows the univariate analysis for the
different plasma cytokine concentrations and potential confound-
ing variables (age, sex, pack years, and smoking status). Significant
associations among them were found: EGF and MIP-1b with
Table 1. Clinical and physiological characteristics of smokers and former smokers without airway obstruction: without
emphysema vs. with emphysema.
WithoutEmphysema(n=0) WithEmphysema(n=80) p
Sex(males) 56/79(70.9%) 61/80(76.2%) 0.73
Age(SD) 53.9(4.2) 52.3(8.4) 0.09
Pack-years(SD) 31.4(9.91) 34.2(9.9) 0.21
Smoking(current) 48/74(64.9%) 58/80(72%) 0.55
FVC(L)(SD) 3.87(0.75) 4.26(0.95) 0.03
%FVC(SD) 104.9(14.5) 106.4(13.8) 0.50
FEV1(L)(SD) 3.01(0.58) 3.23(0.74) 0.04
FEV1%(SD) 99(13.7) 99(12.8) 0.78
doi:10.1371/journal.pone.0060260.t001
Table 2. Plasma cytokines levels of smokers and former
smokers without airway obstruction: without emphysema vs.
with emphysema.
Cytokine
WithoutEmphysema
(n=80)
WithEmphysema
(n=80) p
EGF pg/mL 157.5(100.2) 116.96(142.6) 0.06
IL-15 pg/mL 6.44(4.2) 4.88(3.63) 0.02
IL-1rapg/mL 19.23(12.62) 14.84(15.64) 0.04
IL-8 pg/mL 7.33(5.07) 6.63(4.38) 0.01
MCP-1 pg/mL 216.2(78.8) 210.43(91.67) 0.46
MIP-1b pg/mL 69.55(35.91) 68.73(41.39) 0.09
TGF-a pg/mL 3.18(4.62) 3.97(7.88) 0.27
TNF-a pg/mL 8.06(4.49) 6.95(4.23) 0.16
VEGF pg/mL 158.8(163.6) 163.0(216.9) 0.18
Cytokines levels are shown with their median and IQR (interquartile range).
doi:10.1371/journal.pone.0060260.t002
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gender, VEGF with age, and TGFa with smoking status.
Cumulative tobacco exposure was not associated with cytokine
plasma levels.
Table 4 shows the multivariate analysis of each of the measured
cytokines in the study group, using smokers without emphysema as
a putative control group. Regression coefficients showed that,
compared to smokers without emphysema, subjects with emphy-
sema had lower levels of EGF (20.317, p = 0.01), IL-15 (20.219,
p = 0.01), IL-8 (20.180, p = 0.02), and IL-1ra (20.220, p = 0.03).
Interestingly, gender also had an influence on EGF (0.31,
p = 0.01), IL-1ra (20.19, p = 0.05) and MIP-1b (0.12, p = 0.03)
levels, while age and smoking status had an influence on VEGF
(22.06, p = 0.04) and TGFa (2.29, p = 0.02), respectively.
Discussion
The main finding of this study is that in current and former
smokers without airway obstruction on a spirometry, the presence
of emphysema detected on a CT is associated with changes in
levels of certain cytokines. The differences found include lower
levels of certain cytokines that may result in activation of apoptosis
(EGF, IL-15) and altered immunosurveillance (IL-15, IL-1ra).
The presence of an abnormal systemic inflammatory response
in some patients with stable COPD is a well-recognised
phenomenon [17,18,19]. However, little is known about the
specific impact airway obstruction or emphysema may have on
this systemic inflammatory response. Bon et al. [19], published
data regarding peripheral blood biomarker patterns in subjects
with CT detected airway thickening and emphysema. The study
enrolled two hundred and thirty four current and former smokers
participating in a Lung Cancer Screening Study. Each subject
underwent spirometry and chest CT imaging. Thirty-three
different chemokines and growth factors were measured in serum.
The authors found that certain inflammatory biomarkers were
associated with distinct phenotypic expressions of disease such as
airway remodelling or CT detected emphysema. In particular,
emphysema defined by parenchymal voxels with computed
attenuation values less than 2950 Hounsfield Units (HU) was
associated with higher blood levels of IL-6 and MMP-7, but lower
TNFa levels. In the present work we did not find any association
between emphysema and TNFa levels, and IL-6 and MMP-7 were
not determined. Papaioannou et al. [20], also reported that
COPD patients with CT detected emphysema show an increased
systemic oxidative stress response and harbour elevated fibrinogen
levels, suggesting that clinical differences in the phenotypic
expressions of tobacco related pulmonary disease correlate with
discordant inflammatory response profiles. The methodology of
our study is somewhat different since we chose to focus on the
effect of emphysema, and thus selected only individuals without
airway obstruction for both the study and the control groups
[19,20]. Several authors including our group have reported that a
significant proportion of individuals participating in lung cancer
screening studies have emphysema without airway obstruction
[5,6,21]. We believe that this particular group of individuals
provide an opportunity to study potential mechanisms uniquely
involved in the development of emphysema.
EGF is a soluble growth factor implicated in the regulation of
airway mucus secretion, repair, angiogenesis, and remodelling
[17]. Recent data from research performed in the homozygous
mutant klotho (KL[2/2]) mouse suggest that increased apoptosis
of airway cells via the inhibition of the EGF-dependent pathway
Table 3. Univariate analysis for the different measured plasma cytokine levels.
Cytokine Sex Age Pack-years Smoking(current)
b pvalue b pvalue b pvalue b pvalue
EGF 0.282* 0.01 21.330 0.18 0.241 0.81 0.361 0.71
IL-15 20.473 0.63 20.194 0.84 20.871 0.38 21.172 0.24
IL-1ra 20.064 0.12 0.201 0.84 0.332 0.74 20.624 0.53
IL-8 0.445 0.65 20.581 0.56 20.021 0.98 20.092 0.92
MCP-1 20.710 0.47 21.510 0.13 1.592 0.11 1.321 0.18
MIP-1beta 2.26* 0.02 0.071 0.94 0.092 0.92 20.652 0.51
TGFa 0.210 0.83 21.110 0.27 0.242 0.80 2.29* 0.02
TNF-alfa 1.542 0.12 0.362 0.72 0.782 0.43 21.042 0.30
VEGF 0.111 0.98 22.06* 0.04 1.502 0.13 1.652 0.10
*Statistically significant; b = regression coefficient.
Cytokines levels were log transformed for the analysis.
doi:10.1371/journal.pone.0060260.t003
Table 4. Multivariate analysis of each of the measured
cytokines in the study group, using smokers without
emphysema as a putative control group.
Cytokine EmphysemaNoAirwayObstruction
b p value
EGF 20.317* 0.01
IL-15 20.219* 0.01
IL-1ra 20.220* 0.03
IL-8 20.188* 0.02
MCP-1 20.012 0.83
MIP-1beta 20.068 0.26
TGF-alfa 0.234 0.10
TNF-alfa 20.137 0.08
VEGF 0.039 0.75
*Statistically significant; b = regression coefficient.
Analysis adjusted for sex (EGF, MIP-1beta), age (VEGF) and smoking status (TGF-
alfa) because these factors were statistically significant in the univariate analysis.
Cytokines levels were log transformed for the analysis.
doi:10.1371/journal.pone.0060260.t004
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may be involved in the development of the aging lung process that
includes emphysema [22]. Moreover, EGF receptor serum levels
are reduced in individuals with non-small cell lung carcinoma
[23], while mutations of the EGF receptor have led to targeted
therapies in the treatment of lung adenocarcinoma [24]. Our
findings of decreased levels of EGF in patients with emphysema
are in line with this interesting bio-pathological pathway [25].
IL-15 is a pluripotent antiapoptotic cytokine implicated in both
the innate and adaptive immune response to viral infection and
cancer, and has been postulated as a highly promising immuno-
modulatory agent in cancer therapy [25]. IL-15 regulates cell
proliferation, survival, and function of NK cells. Plasma levels of
this cytokine are reduced in smokers [26]. IL-15 also favours
muscle fibre hypertrophy and antagonises the muscle protein
wasting typically seen in patients with cancer [27] or with
emphysema [28].
The lower levels of IL-15 found in subjects with emphysema
could possibly reflect impaired tumour immunosurveillance and
thus be implicated in their well-known increased risk of lung
cancer [29].
IL-1ra is an anti-inflammatory protein synthesised by hepato-
cytes that downregulates the inflammatory response [30]. Studies
in transgenic and knockout mice indicate that IL-1ra is an
important component of the host defence against endotoxin-
induced injury and plays a key role in the modulation of IL-1
activity, a potent stimulator of metalloproteinases [31]. IL-1
suppression by IL-1ra results in a long-term beneficial effect in
chronic inflammatory diseases [31]. Depressed levels of this
cytokine in patients with emphysema might imply an inability to
downregulate the chronic inflammatory response. Other investi-
gators have reported similar findings in smokers [32] and in
patients with COPD [33]. Interestingly, IL-1ra gene polymor-
phisms have been linked in a Norwegian study to an increased risk
of non-small lung cancer [34].
IL-8 is a neutrophil chemoattractant and activator that induces
a rise in intracellular calcium concentration and exocytosis with
release of enzymes and proteins from intracellular organelles. It
also has chemoattractant properties for T-cells. Up to 43% of the
chemotactic activity of sputum can be attributed to IL-8 [15]. In
patients with COPD, IL-8 levels are usually increased. In our
study, levels of IL-8 were lower in individuals with emphysema,
suggesting that the mechanisms involved in the pathogenic process
are different than in patients with airflow obstruction.
Study Limitations
Our study is limited by the relatively small number of subjects
enrolled; although to our knowledge it is the only study thus far
that evaluates the inflammatory profile of patients with emphy-
sema but without COPD according to current accepted criteria.
We believe it to be hypothesis-generating work, which needs to be
reproduced in larger populations and perhaps with more
mechanistic methodologies. Errors in data interpretation are
another important limitation of any cross-sectional study. Specific
cytokine profiles, for example, may be viewed as either a cause or a
consequence of a given phenotypic expression of a disease. It is
impossible to know which is which without additional longitudinal
studies investigating cytokine profiles in subjects encompassing the
entire spectrum of disease severity.
Conclusions
In conclusion, our study suggests that current and former
smokers with CT-detected emphysema and normal spirometry
have a distinct cytokine profile when compared to subjects without
emphysema. Lower levels of EGF, IL-15, and IL-1ra may be
involved in the activation of apoptosis or in the impairment of
immunosurveillance, two mechanisms that lead to a higher lung
cancer risk. Larger prospective studies are needed to support our
findings, and to investigate whether discordant cytokine profiles
might account for variations in the systemic manifestations within
a given population.
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